2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

904. Outcomes Research: Hemoglobinopathies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4433 Transfusion practices and maternal-perinatal outcomes in sickle cell disease: A multicenter cohort study

Abul Andres Ariza-Manzano, MD, Bria Carrithers, M.D., M.S.2, Valentina Restrepo, M.D.3, Meesha Vullikanti, MS4, Alexandra Galls, MD5, Ryan Hunt, M.D.6, Maureen Okam Achebe Jr, MD, MPH7, Sharl Azar, MD8, Nancy Berliner Jr, MD9, Jean M. Connors, MD10, Elizabeth Klings, MD11, Arielle Lyon Langer, MD MPH12, Thomas F McElrath, MD, PhD13, Deborah Michelle Siegal, MD MSc FRCPC14, Lauren E Merz, MD, MSc15, Layla N. Van Doren, MD, MBA16
1 University of Miami, Fort Lauderdale, Florida, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 Yale New Haven Hospital, New Haven, Connecticut, United States
4 Yale School of Medicine, New Haven, Connecticut, United States
5 Brigham and Women’s Hospital, Boston, Massachusetts, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 Brigham and Women’s Hospital, Boston, Massachusetts, United States
8 Massachusetts General Hospital, Boston, Massachusetts, United States
9 Brigham and Women’s Hospital, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, United States
12 Brigham and Women’s Hospital, Boston, Massachusetts, United States
13 Brigham and Women’s Hospital, Boston, Massachusetts, United States
14 University of Ottawa, Ottawa, Ontario, Canada
15 University of Michigan, Ann Arbor, Michigan, United States
16 University of California, San Francisco, San Francisco, California, United States

Background: Pregnancy in sickle cell disease (SCD) is associated with adverse pregnancy outcomes and increased maternal and neonatal morbidity/mortality. Red blood cell transfusion may mitigate complications by improving anemia and reducing sickling-related physiology; however, transfusion practices vary widely. Prior studies of planned transfusion strategies vs on-demand transfusion have shown inconsistent results. Data demonstrating maternal and perinatal outcomes following transfusion is limited. In this study we evaluated the association of planned, on-demand, and no transfusion strategies with maternal and perinatal outcomes in a multicenter pregnancy-level SCD cohort.

 Methods: We conducted a multi-institutional retrospective-prospective cohort study of 165 pregnancies of people with SCD from 2015 to 2025 across 3 academic tertiary care health centers. Pregnancies were categorized into three mutually exclusive groups by transfusion strategy during pregnancy: planned transfusion (simple or exchange), on-demand transfusion (as needed), and no transfusion. Baseline characteristics, pre-pregnancy transfusion history, and maternal and neonatal outcomes were compared across groups. Multivariable models were adjusted for maternal age, study center, genotype, and pre-pregnancy hemoglobin (Hb). HbS percentage was not included due to high rates of missing data. Standard errors were clustered by patients to account for multiple pregnancies from the same individual. Modified Poisson regression was used for binary outcomes to estimate adjusted risk ratios, and linear regression was used for continuous outcomes to estimate adjusted mean differences.

 Results: Among 165 SCD pregnancies, HbSS made up most of the cohort 83/165 (50%), HbSC 49/165 (30%), HbSβ⁺ 21/165 (13%), and HbSβ⁰ 10/165 (6%). Twenty-nine (17.6%) received planned transfusions, 73 (44%) on-demand, and 63 (38%) no transfusion. Median (IQR) age in the cohorts was 32[29-39] planned, 34[31-39] on-demand, 37[31-41] no transfusion. In the year before conception, 64% of the planned transfusion group received RBC transfusions, compared with 25% in the on-demand and 7% in the no-transfusion group. The planned transfusion group appeared clinically more severe at baseline (requiring exchange or 5+ simple transfusions within the year prior to conception), compared to on-demand and no transfusion (56%, 9%, 0%; p <0.001). HbSS received the majority of planned or on-demand transfusions (76% and 62%) while HbSC made up most of the no transfusion group (54%). Of the 73 pregnancies that received an on-demand transfusion, the most common reasons for transfusion were below target Hb 53/73 (73%), acute chest syndrome or vaso-occlusive episode 32/73 (44%), and delivery complications, including postpartum hemorrhage 30/73 (41%).

After adjusting for age, center, genotype, and pre-pregnancy Hb, planned transfusion was associated with a lower risk of antepartum SCD-related admissions during pregnancy compared with on-demand (aRR 0.77, 95% CI 0.60–0.99; P=0.040) and lower risk of preterm delivery <37 weeks (aRR 0.38, 95% CI 0.15–0.97; P=0.044). Planned transfusion was also associated with longer gestation by 2.45 weeks (95% CI +1.49 to +3.41; P<0.001) and higher birth weight +0.50 kg (95% CI +0.30 to +0.70; P<0.001) compared with on-demand. The on-demand group had a higher risk of SCD admission during pregnancy (aRR 1.85, 95% CI 1.17–2.90; P=0.008), preeclampsia/eclampsia (aRR 2.89, 95% CI 1.24–6.74; P=0.014), and intrauterine growth restriction (aRR 3.18, 95% CI 1.33–7.62; P=0.009) compared with the no transfusion group. The planned transfusion group showed no significant differences in these outcomes compared with the no-transfusion group.

Conclusions: In this multicenter cohort of SCD pregnancies, planned transfusion was associated with fewer SCD-related admissions, lower risk of preterm delivery, longer gestation, and higher birth weight compared with on-demand transfusion. Despite more severe SCD at baseline in the planned transfusion group, requiring more pre-pregnancy transfusions, outcomes were more favorable with the planned strategy compared with on-demand, and no difference in outcomes compared with the no-transfusion group (less severe SCD).   Our findings signal that those with severe SCD benefit from a planned transfusion strategy during pregnancy. Future work should explore the impact of disease severity and early, planned antepartum intervention in patients with SCD.  

Abul Andres Ariza-Manzano, MD: No relevant conflicts of interest to declare.